Hamps Bio (544312)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue growth of 12.71% shows some demand traction.
• Latest quarter sales of ₹4 Cr demonstrate an operating base, albeit tiny.
• ROCE is positive at 6.68%, suggesting the existing asset base is not wholly idle.
• Microcap size of ₹16 Cr leaves room for a genuine operational turnaround to move the needle.

Concerns

• P/E of 0.00 with profit growth of -174.07% indicates the company is loss-making.
• Latest quarter net profit is negative, confirming no current profitability.
• Piotroski F-Score of 4/9 points to weak financial health.
• Critical data such as book value, debt/equity, promoter holding, and 52-week range are missing, making valuation and governance assessment impossible.

AI Analysis

This looks like a business I would struggle to understand deeply. Hamps Bio is a ₹16 crore microcap in agricultural products. The first red flag is earnings: P/E is zero because there are no positive earnings, and profit growth has collapsed by 174.07%. In the latest quarter, sales were ₹4 crore but net profit was a loss, even if small. Graham would say the margin of safety cannot be found in a business that cannot generate returns for shareholders. The top line is growing at 12.71%, and ROCE is 6.68%. That is not terrible, but it is well below what a quality compounder should deliver. With a Piotroski F-score of 4 out of 9, the financial health is weak. I also lack book value, debt-to-equity, promoter holding and a 52-week range. Without those, I cannot assess leverage, insider ownership, or historical valuation. In investing, what you don't know matters as much as what you do. Is this a turnaround? It might be. But buying a turnaround requires a strong balance sheet and a clear path to profits. I see neither here. Sales growth is a positive, but growth without profits consumes cash and destroys shareholder value. At ₹18.81, the market is pricing it like a lottery ticket, not a business. If Hamps Bio can cut costs, improve margins, and show consistent profitable quarters, it will deserve research. Until then, this belongs to the 'too hard' pile. I would wait for evidence of earnings recovery and better disclosure before deploying capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer